Empagliflozin in heart failure with preserved ejection fraction: decoding its molecular mechanism of action using artificial intelligence

Back

HFA Premium Access

Empagliflozin in heart failure with preserved ejection fraction: decoding its molecular mechanism of action using artificial intelligence

Session: Chronic Heart Failure - Pathophysiology and Mechanisms 1

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Doctor O. Iborra Egea (Badalona, ES)

Event: Heart Failure 2021

Congress Presentation

Add to my library

About the speaker

Doctor Oriol Iborra Egea

Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona (Spain)

2 presentations

0 follower

9 more presentations in this session

Real world analysis of outcomes of remote pulmonary artery hemodynamic monitoring in overweight and obese patients with heart failure

Speaker: Doctor M. Oberoi (Sioux Falls, US)

Multicenter nationwide study of the prevalence of ATTR-CM in HFpEF in Spain. Intermediate results from national PRACTICA study.

Speaker: Doctor J. Garcia-Pinilla (Malaga, ES)

HDAC6 inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction

Speaker: Mr J. Yang (South San Francisco, US)

Pulmonary hypertension in heart failure with preserved ejection fraction: the TOPCAT Americas and PARAGON-HF studies

Speaker: Doctor K. Jering (Boston, US)

Access

Abstract

Slides

Changes in natriuretic peptide and effects of vericiguat in worsening heart failure with reduced ejection fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF)

Speaker: Doctor J. Ezekowitz (Edmonton, CA)

Access the full session

Chronic Heart Failure - Pathophysiology and Mechanisms 1

Speakers: Doctor O. Iborra Egea, Doctor M. Oberoi, Doctor J. Garcia-Pinilla, Mr J. Yang, Doctor K. Jering...

Access

About the event

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources